During their second pregnancy with diagnosed HIV (n U 1177), two-fifths of women in the UK/Ireland not on antiretroviral therapy (ART) at conception had an immunological indication for treatment (CD4 R <350 cells/ml), of whom nearly half had CD4
R at least 350 cells/ml in their previous pregnancy. Those initiating ART during pregnancy had a 4.3-fold increased odds of detectable viral load at delivery compared with those conceiving on treatment, suggesting that continuation of ART after pregnancy may be beneficial for many women.
HIV-positive pregnant women not requiring treatment for their own health may take short-course antiretroviral therapy (ART) to prevent vertical transmission [1, 2] . Although this is an effective prevention measure [3] [4] [5] , increased morbidity and mortality among people randomized to scheduled HIV treatment interruptions have been reported in non-pregnant populations [6, 7] , which may have implications for optimal management of HIV in childbearing women. WHO guidelines provide the option of lifelong ART for pregnant women, irrespective of health status ('option Bþ') [8, 9] . Pregnancy incidence among HIV-positive women in the UK is increasing [10] , partly driven by the growing number of women having repeat pregnancies [11] . National surveillance data on diagnosed HIV-positive women reported with more than one pregnancy provide the opportunity to investigate immunological status at the start of second pregnancy, and viral suppression by delivery, in women not on ARTat conception. This helps address the question of whether lifelong ART might be beneficial for all pregnant women.
In the UK/Ireland, pregnancies in diagnosed HIVpositive women are reported to the National Study of HIV in Pregnancy and Childhood (NSHPC) as described elsewhere [12] . We analysed data on repeat pregnancies (second reported since HIV diagnosis) during 2000-2010 in women not on ART at conception (53% of second pregnancies). First antenatal CD4 þ cell counts, prior to ART initiation, were used. UK national guidelines have recommended a treatment threshold of less than 350 cells/ml since 2008 [13, 14] . For analyses exploring detectable maternal viral load at delivery (50 copies/ml), the comparison group comprised second pregnancies (resulting in live/stillbirth) to women conceiving on ART. Multivariable analyses were conducted using forwardfitted logistic regression models in STATA 12.0 (StataCorp, College Station, Texas, USA).
The main study group consisted of 1177 pregnancies to women not on treatment at conception; 1063 resulted in a live or stillbirth. Most (76.0%) were in women from sub-Saharan Africa, median age was 30. Our results should be interpreted in the light of some international guidelines now recommending ART initiation regardless of CD4 þ cell count [15, 16] , and the debate around potential benefits and risks of option Bþ [17] . Here, two-fifths of women not on ART at conception of their second pregnancy had an immunological indication for treatment according to current UK guidelines [13, 14] . For some, this may reflect disengagement from HIV care postnatally, which needs addressing, 1370 AIDS 2014, Vol 28 No 9 particularly for women initiating ART late in their subsequent pregnancy. Possible barriers to access include stigma, fear of disclosure, and childcare responsibilities [18] [19] [20] . It is also salient that a quarter of women with CD4 þ at least 350 cells/ml at their first pregnancy had fallen below the treatment threshold by their second pregnancy. Significant levels of disease progression after discontinuation of antenatal ART have been reported elsewhere [21] [22] [23] [24] . Longer duration of antenatal ART decreases risk of detectable viral load at delivery, and hence the risk of vertical transmission [4, 5, [25] [26] [27] , but the four-fold increased odds of detectable virus among those initiating ART during, rather than before, pregnancy is striking.
In conclusion, these findings suggest that in terms of maternal health and vertical transmission, continuation of ART post-natally could have benefits for many HIVpositive women and their future pregnancy outcomes. However, this needs consideration in the broader context of issues such as potential toxicity (particularly firsttrimester ART exposure), adherence, drug resistance, obstetric outcomes, and women's views and preferences.
